| Title |
Biomarkers for the Diagnosis, Prognosis, and Evaluation of Treatment Efficacy for Traumatic Brain Injury
|
|---|---|
| Published in |
Neurotherapeutics, January 2010
|
| DOI | 10.1016/j.nurt.2009.10.019 |
| Pubmed ID | |
| Authors |
Pramod K. Dash, Jing Zhao, Georgene Hergenroeder, Anthony N. Moore |
| Abstract |
Traumatic brain injury (TBI) remains a serious health concern, and TBI is one of the leading causes of death and disability, especially among young adults. Although preventive education, increased usage of safety devices, and TBI management have dramatically increased the potential for surviving a brain injury, there is still a need to develop reliable methods to diagnose TBI, the secondary pathologies associated with TBI, and predicting the outcomes of TBI. Biomarkers (changes of amount or activity in a biomolecule that reflect injury or disease) have shown promise in the diagnosis of several conditions, including cancer, heart failure, infection, and genetic disorders. A variety of proteins, small molecules, and lipid products have been proposed as potential biomarkers of brain damage from TBI. Although some of these changes have been reported to correlate with mortality and outcome, further research is required to identify prognostic biomarkers. This need is punctuated in mild injuries that cannot be readily detected using current techniques, as well as in defining patient risk for developing TBI-associated secondary injuries. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 279 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | <1% |
| Australia | 1 | <1% |
| Colombia | 1 | <1% |
| Mexico | 1 | <1% |
| Canada | 1 | <1% |
| Unknown | 273 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 45 | 16% |
| Researcher | 43 | 15% |
| Student > Bachelor | 37 | 13% |
| Student > Master | 27 | 10% |
| Other | 23 | 8% |
| Other | 66 | 24% |
| Unknown | 38 | 14% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 93 | 33% |
| Neuroscience | 36 | 13% |
| Agricultural and Biological Sciences | 30 | 11% |
| Engineering | 20 | 7% |
| Psychology | 15 | 5% |
| Other | 38 | 14% |
| Unknown | 47 | 17% |
Attention Score in Context
This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 February 2023.
All research outputs
#3,722,734
of 25,837,817 outputs
Outputs from Neurotherapeutics
#391
of 1,328 outputs
Outputs of similar age
#18,800
of 177,915 outputs
Outputs of similar age from Neurotherapeutics
#3
of 13 outputs
Altmetric has tracked 25,837,817 research outputs across all sources so far. Compared to these this one has done well and is in the 85th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,328 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 18.5. This one has gotten more attention than average, scoring higher than 68% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 177,915 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 88% of its contemporaries.
We're also able to compare this research output to 13 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 76% of its contemporaries.